Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
September 28, 2015 6:30 AM EDT
-Â Â Par Acquisition Enhances Endo's Position as a Leading Global Specialty Pharmaceutical Company with One of Industry's Fastest Growing Generics Businesses and Establishes Powerful Platform for Future Growth and Strategic M&A
-Â Â Combined U.S. Generics Business Unit to be Named Par Pharmaceutical, an Endo International Company
-Â Â Updated 2015 Full Year Financial Guidance to $3.22 to $3.27 Billion in Revenues; Endo Maintains Upper End of 2015 Adjusted Diluted EPS from Continuing Operations Guidance of $4.50 to $4.60
-Â 2016 Adjusted Diluted EPS from Continuing Operations Expected to be in the Range of... More
September 25, 2015 6:00 AM EDT
DUBLIN, Sept. 25, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that on September 24, 2015, it received notice of termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, from the U.S. Federal Trade Commission in connection with Endo's previously... More
